New York-based Solstice raised $21M in Series A funding led by Transformation Capital, bringing total funding to nearly $25M
The startup uses AI to reduce pharma marketing and regulatory review timelines from months to under 10 days
Solstice already works with over a dozen pharmaceutical companies, including several top 20 global pharma brands
The healthcare and pharmaceutical industry spends more than $100 billion annually on commercialisation and marketing efforts. Yet despite rapid advances in AI across healthcare, pharma marketing workflows remain heavily manual, fragmented, and dependent on lengthy medical, legal, and regulatory (MLR) review cycles. In many cases, even routine assets such as physician emails or patient communications can take three months to gain approval.
Solstice says its AI-native platform reduces that timeline dramatically, enabling pharmaceutical brands to move from content creation to MLR submission in under 48 hours and launch campaigns in roughly 10 days.
